Pharmaceuticals major Zydus today said that its R&D subsidiary Etna Biotech will collaborate with US-based National Institute of Allergy and Infectious Diseases (NIAD) to develop a vaccine against visceral leishmaniasis (VL), known as Kala-Azar in India.
Etna Biotech will also donate $2,40,000 for advancing research under the NIH leishmaniasis programme.
In a BSE filing, Zydus said, “Etna Biotech announced a collaborative programme with the National Institute of Allergy and Infectious Diseases, part of the US National Institutes of Health (NIH) for advancing leishmaniasis research.”
It further said, “Under a separate agreement, Etna Biotech also extended its support of the NIH leishmaniasis programme by donating USD 2,40,000 for research.”
Commenting on the development, Zydus Group Chairman and Managing Director Pankaj R Patel said: “Zydus is proud to collaborate with US NIH to solve the increasing worldwide disease burden of visceral leishmaniasis and to move forward to put a basis for the successful development of a novel candidate vaccine for visceral leishmaniasis.”
Headquartered in Ahmedabad, Zydus Cadila is a global pharmaceutical company that discovers, manufactures and markets a broad range of healthcare therapies.
The Group employs over 16,500 people worldwide, including over 1,600 scientists in R&D.
Cadila Healthcare is part of Zydus Group.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.